The potency of abemaciclib, palbociclib and ribociclib was investigated in a panel of 37 breast cancer cell lines presenting different molecular profiling status, including Rb1 deficiency, ER/AR expression, HER2 amplification, and PIK3CA or BRCA1/2 mutations (Supplementary Table 3). Here, RB1 is linked to breast carcinoma.